{"disease":{"id":"primary-hyperoxaluria-type-i","name":"Primary hyperoxaluria, type I","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"lumasiran","indication_name":"Primary hyperoxaluria, type I","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oxlumo","generic_name":"LUMASIRAN","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"Hydroxyacid oxidase 1 (HAO1) mRNA","drug_class":"","quality_score":59,"revenue":"200","mechanism":"Oxlumo works by binding to and silencing the mRNA that produces the enzyme Hydroxyacid oxidase 1, which is overactive in patients with Primary hyperoxaluria, type I."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT04042402","title":"Long Term Extension Study in Patients With Primary Hyperoxaluria","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":75,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT03847909","title":"A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT04580420","title":"Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT05001269","title":"Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":true},{"nct_id":"NCT04152200","title":"A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}